Yangtze River Pharmaceutical Group Co., Ltd.
Records under this name other than the patents Yangtze River Pharmaceutical Group Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 18 patents it holds.
Back to Yangtze River Pharmaceutical Group Co., Ltd.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,696,228 | Oral preparation of dyclonine hydrochloride Term ended Term ended Jun 16, 2026 · USPTO record | Term ended | Term ended Jun 16, 2026 | USPTO record |
| US 9,890,168 | 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof Lapsed on the fee record Ended Feb 13, 2026 · USPTO record | Lapsed on the fee record | Ended Feb 13, 2026 | USPTO record |
| US 9,879,008 | 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof Lapsed on the fee record Ended Jan 30, 2026 · USPTO record | Lapsed on the fee record | Ended Jan 30, 2026 | USPTO record |
| US 7,745,433 | 2-Substituted phenyl-5, 7-dihydrocarbyl-3, 7-dihydropyrrolo [2, 3-D] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof Term ended Term ended Dec 30, 2025 · USPTO record | Term ended | Term ended Dec 30, 2025 | USPTO record |
| US 11,174,254 | Aniline-substituted 1,2-dihydropyrrol[3,4-C]pyridin/pyrimidin-3-one derivative and use thereof Lapsed on the fee record Ended Nov 16, 2025 · USPTO record | Lapsed on the fee record | Ended Nov 16, 2025 | USPTO record |
| US 11,168,088 | Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof Lapsed on the fee record Ended Nov 9, 2025 · USPTO record | Lapsed on the fee record | Ended Nov 9, 2025 | USPTO record |
| US 11,155,546 | 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof Lapsed on the fee record Ended Oct 26, 2025 · USPTO record | Lapsed on the fee record | Ended Oct 26, 2025 | USPTO record |
| US 11,104,664 | 4,5,6-trisubstituted indazole derivatives, and preparation method and pharmaceutical use thereof Lapsed on the fee record Ended Aug 31, 2025 · USPTO record | Lapsed on the fee record | Ended Aug 31, 2025 | USPTO record |
| US 8,461,165 | 2-Substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof Lapsed on the fee record Ended Jun 11, 2025 · USPTO record | Lapsed on the fee record | Ended Jun 11, 2025 | USPTO record |
| US 10,947,202 | Sodium ion channel inhibitors and pharmaceutically acceptable salts and polymorphs thereof and uses thereof Lapsed on the fee record Ended Mar 16, 2025 · USPTO record | Lapsed on the fee record | Ended Mar 16, 2025 | USPTO record |